These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25446280)

  • 1. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
    Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM
    Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
    Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
    Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
    Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
    Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
    Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P
    Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
    Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
    Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
    Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF
    Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.
    Naing A; Lorusso P; Fu S; Hong D; Chen HX; Doyle LA; Phan AT; Habra MA; Kurzrock R
    Br J Cancer; 2013 Mar; 108(4):826-30. PubMed ID: 23412108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
    Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
    J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
    Weigel B; Malempati S; Reid JM; Voss SD; Cho SY; Chen HX; Krailo M; Villaluna D; Adamson PC; Blaney SM
    Pediatr Blood Cancer; 2014 Mar; 61(3):452-6. PubMed ID: 23956055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
    McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
    Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
    Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
    Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.
    Morgenstern DA; Marzouki M; Bartels U; Irwin MS; Sholler GL; Gammon J; Yankanah R; Wu B; Samson Y; Baruchel S
    Pediatr Blood Cancer; 2014 Jan; 61(1):128-33. PubMed ID: 23956145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Rheingold SR; Tasian SK; Whitlock JA; Teachey DT; Borowitz MJ; Liu X; Minard CG; Fox E; Weigel BJ; Blaney SM
    Br J Haematol; 2017 May; 177(3):467-474. PubMed ID: 28295182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
    Becher OJ; Gilheeney SW; Khakoo Y; Lyden DC; Haque S; De Braganca KC; Kolesar JM; Huse JT; Modak S; Wexler LH; Kramer K; Spasojevic I; Dunkel IJ
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma.
    Thornton KA; Chen AR; Trucco MM; Shah P; Wilky BA; Gul N; Carrera-Haro MA; Ferreira MF; Shafique U; Powell JD; Meyer CF; Loeb DM
    Int J Cancer; 2013 Aug; 133(4):997-1005. PubMed ID: 23382028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
    Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
    Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.